רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

ROTAVIRUS G1 REASSORTANT; ROTAVIRUS G2 REASSORTANT; ROTAVIRUS G3 REASSORTANT; ROTAVIRUS G4 REASSORTANT; ROTAVIRUS P1A[8] REASSORTANT

Disponível em:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Código ATC:

J07BH

Forma farmacêutica:

SUSPENSION

Composição:

ROTAVIRUS P1A[8] REASSORTANT 2.3 X10 ^6 IU/DOSE; ROTAVIRUS G2 REASSORTANT 2.8 X10 ^6 IU/DOSE; ROTAVIRUS G4 REASSORTANT 2.0 X10^ 6 IU/DOSE; ROTAVIRUS G3 REASSORTANT 2.2 X10 ^6 IU/DOSE; ROTAVIRUS G1 REASSORTANT 2.2 X10 ^6 IU/DOSE

Via de administração:

פומי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

MERCK SHARP & DOHME CORP., USA

Grupo terapêutico:

ROTA VIRUS DIARRHEA VACCINES

Indicações terapêuticas:

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RoraTeq should be administered betwen 6 and 12 weeks of age.

Data de autorização:

2022-05-31